Most Read Articles
4 days ago
Ivermectin confers benefits in the treatment of COVID-19, with a recent study showing that its use helps reduce the risk of death especially in patients with severe pulmonary involvement.
3 days ago
Mental health comorbidities are common among patients with type 2 diabetes mellitus and may lead to worse outcomes, a recent study has found.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Tristan Manalac, 18 Nov 2020
The substitution of isoleucine to leucine at amino acid 97 (I97L) in the core region of the hepatitis B virus (HBV) seems to reduce its potency, decreasing the efficiency of both infection and the synthesis of the virus’ covalently closed circular (ccc) DNA, reports a new study presented at The Liver Meeting Digital Experience by the American Association for the Study of Liver Diseases (AASLD 2020).

Inflammatory indices help gauge efficacy of atezolizumab against NSCLC

24 Oct 2020

Inflammatory indices, such as the neutrophil-to-lymphocyte (NLR) and lymphocyte-to-monocyte (LMR) ratios, may help determine the efficacy of atezolizumab monotherapy in patients with nonsmall cell lung cancer (NSCLC), a recent study has found.

The researchers conducted a retrospective review of 81 NSCLC patients (median age, 71 years; 54.3 percent male) treated with atezolizumab. Most of the participants had stage IV (63.0 percent) and III (23.5 percent) disease; 11 patients (13.6 percent) had pot-surgery recurrence.

No patients had complete response to atezolizumab, as defined by the Response Evaluation Criteria in Solid Tumours. On the other hand, almost half (46.9 percent) achieved a stable disease, while 7.4 percent showed partial response. More than a third were deemed to have progressive disease.

The resulting objective response rate was low at 7.4 percent, though the disease control rate was 54.3 percent. The median progression-free (PFS) and overall survival (OS) values were 60 and 252 days, respectively.

Log-rank evaluation showed that patients with NLR >5 and LMR ≤1.5 saw significantly shorter PFS than counterparts with NLR ≤5 (42 vs 86 days; p<0.001) and LMR >1.5 (37 vs 84 days; p=0.0031). The same was true for those with platelet-to-lymphocyte ratio of >262 vs ≤262 (48.5 vs 90 days; p=0.033). Similarly, OS was significantly shortened when using the same cutoffs.

Multivariate analysis further confirmed that a high NLR at baseline was associated with significantly worse PFS (hazard ratio [HR], 2.50, 95 percent confidence interval [CI], 1.40–4.56; p=0.0018) and OS (HR, 2.91, 95 percent CI, 1.51–5.61; p=0.0014).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
4 days ago
Ivermectin confers benefits in the treatment of COVID-19, with a recent study showing that its use helps reduce the risk of death especially in patients with severe pulmonary involvement.
3 days ago
Mental health comorbidities are common among patients with type 2 diabetes mellitus and may lead to worse outcomes, a recent study has found.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Tristan Manalac, 18 Nov 2020
The substitution of isoleucine to leucine at amino acid 97 (I97L) in the core region of the hepatitis B virus (HBV) seems to reduce its potency, decreasing the efficiency of both infection and the synthesis of the virus’ covalently closed circular (ccc) DNA, reports a new study presented at The Liver Meeting Digital Experience by the American Association for the Study of Liver Diseases (AASLD 2020).